<DOC>
	<DOCNO>NCT00423059</DOCNO>
	<brief_summary>Recently , intravitreal bevacizumab ( Avastin ) injection gain popularity potential treatment intraocular neovascularization ( CNV ) associate age relate macular degeneration diabetic retinopathy . The efficacy drug think related pharmacologic blockade VEGF . The purpose study determine effect intravitreal bevacizumab fibrovascular membrane associate proliferative diabetic retinopathy objective histologic evaluation . The patient schedule vitrectomy tractional fibrovascular membrane due proliferative diabetic retinopathy randomize two treatment group . The one receive conventional vitrectomy group receive intravitreal bevacizumab injection one week schedule vitrectomy . The fibrovascular membrane excise surgery fixate histologic examination . The expression VEGF PEDF , potent inhibitor angiogenesis , evaluate fibrovascular membrane immunohistochemistry . The result compare two treatment group .</brief_summary>
	<brief_title>Intravitreal Bevacizumab Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Tractional retinal detachment recently involve macula fibrovascular membrane due proliferative diabetic retinopathy Severe fibrovascular proliferation progress appropriate panretinal photocoagulation Uncontrolled systemic hypertension Recent history myocardiac infarction within 6 month Recent history cerebrovascular accident within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>intravitreal bevacizumab</keyword>
	<keyword>proliferative diabetic retinopathy</keyword>
	<keyword>VEGF</keyword>
	<keyword>PEDF</keyword>
</DOC>